An Absolute Bioavailability Study of LY2140023 and LY404039 in Healthy Subjects Using the Intravenous Tracer Method
Phase of Trial: Phase I
Latest Information Update: 09 Aug 2012
At a glance
- Drugs LY 404039 (Primary) ; LY 404039 (Primary) ; Pomaglumetad methionil (Primary) ; Pomaglumetad methionil (Primary)
- Indications Schizophrenia
- Focus Pharmacokinetics
- 09 Aug 2012 Actual end date (Jul 2012) added as reported by ClinicalTrials.gov.
- 31 Jul 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Jul 2012 New trial record